Billions are pouring into AI drug discovery. Zero approved drugs. But that's about to change. Retro Bio Head of Applied AI Rico Meinl explains protein engineering, virtual cells, autonomous laboratories, AI co-scientists, why generating “black-box data” may matter more than building larger models, and what's required to turn AI breakthroughs into drugs that actually work. Hosted by Mgoes → https://x.com/m_goes_distance Brought to you by SuperHuman Fund → https://superhuman.fund/ --- 00:00 - Zero AI Drugs Approved 05:05 - Retro’s 50x 09:38 - The AlphaFold Moment 13:47 - Black Box Data 21:23 - The Ladder: Proteins to Cells 25:02 - Are Virtual Cells Overhyped? 32:53 - Hitting the Clinical Wall 35:58 - AWS for Biotech 46:16 - The Real Inflection Point 49:30 - The Anti-Scaling Law 54:25 - AI Co-Scientists 1:03:32 - Real vs hype --- The Accelerate Bio Podcast explores the future of humanity in the age of Artificial Intelligence. Subscribe for deep-dive conversations with founders, scientists, and investors shaping AI, biotechnology, and human enhancement. --- This episode discusses AI drug discovery, Rico Meinl, Retro Biosciences, Retro Bio, AI biotech, AI-discovered drugs, OpenAI biology, cellular reprogramming, Yamanaka factors, longevity biotechnology, protein engineering, protein language models, AlphaFold, virtual cells, single-cell RNA sequencing, black-box data, autonomous labs, AI co-scientist, lab automation, drug development, clinical trials, antibody engineering, small molecules, TechBio, computational biology
